Gelonghui May 27 丨 Hongyuan Pharmaceutical (301246megadicelotto.SZ) said on the investor interaction platform that the company is currently not prepared through synthetic biology technologymegadicelottoproducts. In addition, the "Wuhan R & D Center Expansion Project" implemented by Hubei Hongyuan Chemical Technology Co., Ltd., a wholly-owned subsidiary of the company, will build chemical research platforms including impurity research, crystal form research, synthetic biology research, asymmetric synthesis and continuous flow, as well as preparation research technology platforms such as tablets, capsules, sustained and controlled release and injections. Currently, the project has not yet been completed.
